Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686855 · ClinicalTrials.gov registry record · Phase 2
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
A Phase 2 study of Oral Chronic Graft-versus-host Disease, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 5
- Study locations
NCT00686855 is a Phase 2 study of Oral Chronic Graft-versus-host Disease that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 46 participants. The trial reports 5 study locations across 1 state.
The verdict
NCT00686855, a Phase 2 study of Oral Chronic Graft-versus-host Disease, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this research study is to determine the effectiveness of topical steroid therapy (with a drug called dexamethasone) and topical tacrolimus therapy for the treatment of oral chronic Graft-Versus-Host Disease (cGVHD)
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Tacrolimus
Study Locations (5)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Children's Hospital Boston - Boston
- Dana-Farber Cancer Institute - Boston
- Beth-Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2008-08 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00686855
The ClinicalTrials.gov registry entry for NCT00686855 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oral Chronic Graft-versus-host Disease appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT00686855 reports 5 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00686855 about?
NCT00686855 is a clinical study titled "Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease". The purpose of this research study is to determine the effectiveness of topical steroid therapy (with a drug called dexamethasone) and topical tacrolimus therapy for the treatment of oral chronic Graft-Versus-Host Disease (cGVHD)
What is the current status of trial NCT00686855?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2008-08. Estimated completion is 2013-03.
What conditions does trial NCT00686855 study?
This clinical trial studies the following conditions: Oral Chronic Graft-versus-host Disease.
What interventions are being tested in trial NCT00686855?
The interventions under investigation include: Dexamethasone (DRUG), Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00686855?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00686855 being conducted?
This trial has 5 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.